IDEXX Laboratories, Inc. $IDXX Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 208.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,857 shares of the company’s stock after buying an additional 16,115 shares during the quarter. Cibc World Market Inc.’s holdings in IDEXX Laboratories were worth $16,140,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Marietta Investment Partners LLC increased its stake in IDEXX Laboratories by 185.2% during the fourth quarter. Marietta Investment Partners LLC now owns 1,383 shares of the company’s stock worth $936,000 after acquiring an additional 898 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of IDEXX Laboratories by 28.0% in the 4th quarter. CIBC Asset Management Inc now owns 37,818 shares of the company’s stock valued at $25,585,000 after purchasing an additional 8,274 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of IDEXX Laboratories by 16.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 831,911 shares of the company’s stock valued at $562,813,000 after purchasing an additional 119,969 shares during the last quarter. Bridges Investment Management Inc. grew its holdings in shares of IDEXX Laboratories by 36.6% during the 4th quarter. Bridges Investment Management Inc. now owns 541 shares of the company’s stock worth $366,000 after purchasing an additional 145 shares during the period. Finally, Dynasty Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $237,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. UBS Group lowered their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Finally, Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $562.16 on Friday. The firm has a 50 day moving average of $563.05 and a two-hundred day moving average of $632.14. The stock has a market capitalization of $44.34 billion, a PE ratio of 41.40, a P/E/G ratio of 3.09 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.